Menora Mivtachim Holdings LTD. trimmed its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 126,715 shares of the medical research company’s stock after selling 2,370 shares during the period. Menora Mivtachim Holdings LTD.’s holdings in Amgen were worth $21,602,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of AMGN. Barrow Hanley Mewhinney & Strauss LLC increased its holdings in shares of Amgen by 110.7% during the fourth quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 647 shares of the medical research company’s stock valued at $113,000 after purchasing an additional 340 shares during the period. Braun Bostich & Associates Inc. acquired a new position in shares of Amgen during the first quarter valued at $113,000. WealthTrust Fairport LLC acquired a new position in shares of Amgen during the first quarter valued at $121,000. Cornerstone Advisors Inc. increased its holdings in shares of Amgen by 76.5% during the first quarter. Cornerstone Advisors Inc. now owns 729 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 316 shares during the period. Finally, Taylor Hoffman Wealth Management acquired a new position in shares of Amgen during the fourth quarter valued at $127,000. 78.27% of the stock is currently owned by institutional investors.
Amgen opened at $185.15 on Monday, MarketBeat.com reports. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.88 and a quick ratio of 3.60. Amgen, Inc. has a 1-year low of $163.31 and a 1-year high of $201.23. The firm has a market capitalization of $122.51 billion, a P/E ratio of 14.72, a P/E/G ratio of 2.30 and a beta of 1.38.
In related news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Tuesday, June 12th. The stock was sold at an average price of $184.27, for a total value of $281,011.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 4,575 shares of company stock valued at $809,851 in the last quarter. 0.19% of the stock is currently owned by corporate insiders.
AMGN has been the topic of a number of research analyst reports. BidaskClub raised Amgen from a “sell” rating to a “hold” rating in a report on Friday, May 25th. Barclays lowered their price target on Amgen from $190.00 to $180.00 and set an “equal weight” rating on the stock in a report on Thursday, April 5th. ValuEngine lowered Amgen from a “buy” rating to a “hold” rating in a report on Monday, April 2nd. Mizuho set a $200.00 target price on Amgen and gave the stock a “buy” rating in a report on Tuesday, May 15th. Finally, Cann reaffirmed a “buy” rating on shares of Amgen in a report on Friday, June 8th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Amgen currently has a consensus rating of “Hold” and an average price target of $194.77.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.